Dare Bioscience (DARE) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

DARE Dare Bioscience

Watchlist

0.2892
+0.0032+1.12%

Close Apr 25 16:00 ET

0.2998
+0.0106+3.67%

Post 19:01 ET

29.09MMarket Cap-826P/E (TTM)

Full Hours

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

12 Health Care Stocks Moving In Wednesday's After-Market Session
GainersAcrivon Therapeutics (NASDAQ:ACRV) stock rose 12.3% to $10.67 during Wednesday's after-market session. The market value of their outstanding shares is at $329.4 million. Amarin Corp (NASDAQ:AMR
BenzingaApr 24 16:31 ET
Express News | Daré Bioscience To Receive $1M Installment Under Grant To Advance Development Of DARE-LARC1
Moomoo 24/7Apr 23 08:08 ET
Express News | Dare Bioscience: Under Terms of Grant Agreement, Daré May Get up to About $49 Mln to Support Nonclinical Development of Dare-Larc1
Moomoo 24/7Apr 23 08:07 ET
Express News | Dare Bioscience: To Get $1 Mln as Latest Installment Under Grant Deal to Advance Development of Daré's Investigational Contraceptive Dare-Larc1
Moomoo 24/7Apr 23 08:06 ET
Press Release: Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1
Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1 Dare Bioscience's DARE-LARC1 Platform Technology has Transformative Po
Dow JonesApr 23 08:00 ET
Express News | Dare Bioscience Shares Are Trading Lower After Brookline Capital Downgraded the Stock From Buy to Hold
Moomoo 24/7Apr 17 13:31 ET

Comments

Trytosaveabit

Apr 23 20:09

Short explanation of my LIKE comment! Hehehe

$Dare Bioscience(DARE.US)$ Dare Bioscience: Under Terms of Grant Agreement, Daré May Get up to About $49 Mln to Support Nonclinical Development of Dare-Larc1

Trytosaveabit

Apr 23 20:03

Like

$Dare Bioscience(DARE.US)$ SAN DIEGO, April 23, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced it will receive a payment of $1 million as the latest installment under a grant agreement to advance the development of Daré's investigational contraceptive DARE-LARC1 through nonclinical proof of principle studies and other IND-enabling work to allow for the submission of an Investigational New Drug (IND) Application with the...

Trytosaveabit

Apr 18 01:08

Dangerous play, but!

$Dare Bioscience(DARE.US)$ Great womans health products! Could be a good place to buy! BUT but, be aware shareholders meeting on june 5! Voting on R/S upto a 1-12! But because of the offering causing the big drop. It may be a place to gamble on the Pre R/S pop? Or if you like a bargin? yes R/S more than likely coming but its not supposed to be more than a 1-12 so yes your share count will be lower but your % of loss or gain stays the same! Or if profit shows before R/S sell a...

Trytosaveabit

Apr 11 20:30

Update!

$Dare Bioscience(DARE.US)$ Daré Bioscience Announces Publication In Contraception Of Efficacy And Safety Findings From A Pre-Pivotal Postcoital Test Study Of Ovaprene: An Investigational Hormone-Free Monthly Intravaginal Contraceptive
Benzinga· 11 mins ago
Published data shows that Ovaprene was safe and effective in a postcoital test study of 33 women
Pivotal Phase 3 contraceptive efficacy clinical study of Ovaprene currently enrolling
Ovaprene has the potential to be the first FDA-appro...

Trytosaveabit

Mar 28 20:17

Keep eyes open for this!

$Dare Bioscience(DARE.US)$ Daré is continuing to interact with the FDA as the FDA reviews, specifically, the data generated on the proposed endpoints to take forward into Phase 3 development. The FDA has indicated it anticipates providing additional feedback on the Phase 3 design in 2Q-2024.
Daré's planned Phase 3 study of Sildenafil Cream, 3.6% would be the first ever Phase 3 pivotal study of a therapeutic candidate for the treatment of arousal disorder in women. Daré...